Compare FLUX & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLUX | COCP |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.3M | 14.1M |
| IPO Year | 2019 | 2011 |
| Metric | FLUX | COCP |
|---|---|---|
| Price | $0.52 | $0.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 80.6K | 24.6K |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 20.00 | ★ 54.65 |
| EPS | N/A | ★ N/A |
| Revenue | $9,317,000.00 | ★ $12,712,091.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $23.01 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 126.25 | N/A |
| 52 Week Low | $0.51 | $0.76 |
| 52 Week High | $7.55 | $2.19 |
| Indicator | FLUX | COCP |
|---|---|---|
| Relative Strength Index (RSI) | 29.77 | 29.72 |
| Support Level | N/A | N/A |
| Resistance Level | $1.18 | $1.11 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 16.83 | 33.33 |
Flux Power Holdings Inc design, develop, manufacture, and sell a portfolio of lithium-ion energy storage solutions for electrification of a range of industrial commercial sectors which include material handling, airport ground support equipment (GSE), and other commercial and industrial applications. It offers a high-power battery cell management system(BMS). The company's BMS provides three functions to its battery systems which include Cell Balancing, Monitoring, and Error Reporting.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.